Muutke küpsiste eelistusi

Microbiomes Impact on the Brain: A Paradigm Shift in Neurodegenerative Research [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 391 pages, kõrgus x laius: 235x155 mm, 43 Illustrations, color; 1 Illustrations, black and white
  • Ilmumisaeg: 04-May-2026
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9819574935
  • ISBN-13: 9789819574933
Teised raamatud teemal:
  • Kõva köide
  • Hind: 187,84 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 220,99 €
  • Säästad 15%
  • See raamat ei ole veel ilmunud. Raamatu kohalejõudmiseks kulub orienteeruvalt 3-4 nädalat peale raamatu väljaandmist.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 391 pages, kõrgus x laius: 235x155 mm, 43 Illustrations, color; 1 Illustrations, black and white
  • Ilmumisaeg: 04-May-2026
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9819574935
  • ISBN-13: 9789819574933
Teised raamatud teemal:
This book explores the rapidly advancing field of gutbrain interactions, with a particular focus on the emerging evidence linking the gut microbiome to neurodegenerative diseases such as Alzheimers disease, Parkinsons disease, cerebral palsy, and amyotrophic lateral sclerosis (ALS). As scientific discoveries continue to illuminate how gut microorganisms influence brain structure and function, this work examines the mechanisms through which microbial imbalance contributes to disease onset and progression. By integrating cutting-edge findings on neuroinflammation, immune modulation, metabolic signaling, and neurotransmitter regulation, the book provides a comprehensive analysis of how the gut microbiome may act not only as a contributing factor but also as a promising therapeutic target. Each chapter highlights how disturbances in gut microbial ecology can trigger neuroinflammation, cognitive impairment, and motor neuron degeneration, while also presenting emerging therapeutic strategies including probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation. Ultimately, this book offers an optimistic perspective on the development of microbiome-based, personalized interventions that hold the potential to transform the prevention and treatment of neurological disorders.
Part I.
Chapter
1. The Microbiome-Body Connection: Unveiling the
Gut-Brain Axis.
Chapter
2. Gut Microbiome Imbalance: The Root Cause of
Neurodegeneration?.
Chapter
3. The Vagally Mediated Pathway: How Gut Signals
Affect the Nervous System.
Chapter
4. Parkinsons Disease and the
Microbiome: A New Frontier for Early Diagnosis.
Chapter
5. ALS and the
Microbiome: Understanding the Guts Impact on Motor Neuron Degeneration.-
Chapter
6. The Gut microbiomes alterations in children with cerebral palsy
and Epilepsy.
Chapter
7. The Microbiome and Neurotransmitter Regulation: A
Double-Edged Sword.
Chapter
8. Therapeutic Interventions: Modulating the
Microbiome to Combat Neurodegeneration.- Part II.
Chapter
9. The Role of
Inflammation in the Brain: A Gut-Driven Phenomenon.
Chapter
10. Gut
microbiome and Bile acid interactions: Role play changing neuropsychiatric
illnesses.
Chapter
11. Gut Dysbiosis in Alzheimer's Disease: Insights from
the Microbiome.
Chapter
12. Gut microbiome, Machine learning and Artificial
Intelligence way forward with precision medicine.
Chapter
13. Altering gut
microbiome interactions: Clinical trial results and implications.
Chapter
14. Looking Ahead: The Promise of the Gut Microbiome in Personalized
Neurodegenerative Disease Therapies.
Chapter
15. Gut microbiome in chronic
disorders management.
Chapter
16. Gut microbiome changing foods and
nutrition.
Md. Habibur Rahman, RPh, Ph.D.



Md. Habibur Rahman is a Registered Pharmacist and a member of the Novel Global Community Education Foundation (Australia). He earned his Ph.D. in Medical Science and has contributed his expertise to several leading pharmaceutical organizations. His research is primarily focused on neuroscience, particularly the molecular mechanisms underlying clinical dementia, with emphasis on biomarker discovery and targeted diagnostic strategies. In addition to his neuroscience work, Dr. Rahman is an expert in molecular biology, with extensive experience in gene expression analysis, oxidative stress pathways, and neuroinflammation. He has been recognized among the top 2% of scientists worldwide (Stanford University, citation-based global ranking) for his impactful contributions. Dr. Rahman is also an active scientific communicator and public speaker, frequently presenting at international conferences and academic forums. He serves as a peer reviewer for several high-impact journals and is involved in multiple ongoing research collaborations in neuroscience and molecular medicine.



MUHASINA KM, M Pharm, Ph D  Department of Pharmaceutical Analysis, Prime College of Pharmacy, Palakkad, Kerala, India.



Dr Muhasina K M is a dedicated academician and researcher currently serving as an Associate Professor at Prime College of Pharmacy, affiliated with Kerala University of Health Sciences and Pharmacy Council of India, shaping the next generation of pharmacy professionals through her expertise and commitment to excellence. With a strong academic foundation and specialisation in the field, she has developed a keen research interest in novel drug delivery systems, natural-product-based therapeutics and cancer biology. Her scholarly work reflects a balance of scientific rigour and innovative thinking, contributing to the advancement of Pharmacy education and applied research. 



She has actively participated in various conferences and gained loud applause for her research contributions, and she is actively engaged in interdisciplinary research communities. Her contributions extend beyond academics into mentorship and curriculum development, where she emphasises hands-on learning, critical thinking and research curiosity among students. As an aspiring academician and researcher, she continues to explore emerging trends in pharmaceutical sciences, with a vision to support evidence-based advancement in health care.